NYSE Composite ended the session with Pfizer jumping 1.53% to $37.11 on Monday, following last session’s upward trend. NYSE Composite dropped 0.38% to $14,895.23, after two consecutive sessions in a row of losses, on what was a somewhat negative trend exchanging session today.
Pfizer today’s close was $37.11, 16.09% below its 52-week high of $43.08.
News about Pfizer today
According to today’s article on Business Insider, "Major players in the cellular immunotherapy market are Novartis AG, Gilead Sciences Inc. (Kite Pharma), Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp (GC Pharma), AstraZeneca, Bristol-Myers Squibb, Pfizer Inc. and Roche."
According to today’s article on Bloomberg Quint, "While those two efforts appear to have disappointed, we now know that at least two shots using the newer mRNA technology-from Pfizer Inc.-BioNTech SE and Moderna Inc. -have had much better success and are now at the forefront of the global vaccination effort. "
Pfizer’s sales growth is a negative 6.1% for the ongoing quarter and 3.8% for the next. The company’s growth estimates for the present quarter and the next is a negative 7.3% and a negative 2.5%, respectively.
Year-on-year quarterly revenue growth declined by 4.3%, now sitting on 48.65B for the twelve trailing months.
Pfizer’s last day, last week, and last month’s average volatility was a positive 0.19%, a negative 0.11%, and a negative 0.11%, respectively.
Pfizer’s last day, last week, and last month’s high and low average amplitude percentage was 1.60%, 1.17%, and 1.60%, respectively.
Pfizer’s Stock Yearly Top and Bottom Value
Pfizer’s stock is valued at $37.11 at 16:41 EST, way below its 52-week high of $43.08 and way higher than its 52-week low of $26.45.
Pfizer’s Moving Average
Pfizer’s value is under its 50-day moving average of $37.90 and above its 200-day moving average of $36.10.
Previous days news about Pfizer
According to Bloomberg Quint on Friday, 22 January, "So far the country has administered 567,379 doses of the Pfizer vaccine, Lopez-Gatell reported on Friday morning, but delays in delivery of shots from the company could affect the immunization rate in coming weeks."
According to Bloomberg Quint on Saturday, 23 January, "Bloomberg: In a previous interview with Bloomberg, you said that Pfizer Inc. had turned to the U.S. government to get priority access to raw materials so it could deliver 100 million doses by the second quarter of this year. ", "The consequence of that is the government has much clearer visibility on what Pfizer is doing with those materials. "